Skip to main content

Advertisement

SpringerLink
Log in

Cyclin D3 gene amplification in bladder carcinoma in situ

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

Carcinoma in situ (CIS) is a non-papillary high-grade, potentially aggressive, and unpredictable manifestation of bladder urothelial carcinoma. The aim of this study was to assess patterns of Cyclin D3 gene amplification in Bacillus Calmette-Guerin (BCG)-treated CIS and correlate gene status with recurrence-free and progression-free survival. A sequential cohort series of 28 primary (isolated) or secondary (concomitant) bladder CIS samples in which there was enough tissue material to assess Cyclin D3 gene status by fluorescent in situ hybridization was the study group. Cyclin D3 gene amplification was present in 29% of secondary CIS; none of primary CIS samples had Cyclin D3 gene amplification. Cyclin D3 amplification was related to recurrence- (p = 0.046) and progression-free survival (p = 0.002). Type of bladder CIS (primary vs. secondary) was unrelated to recurrence- or progression-free survival in the current series. Cox’s regression analysis selected Cyclin D3 as an independent predictor of progression-free survival (p = 0.041, relative risk = 61.503, 95% confidence interval = 1.1–274.710). None of primary CIS cases recurred on follow-up; nine secondary CIS recurred and four of them progressed to invasive bladder carcinoma HG T1 (n = 1), T2b N0M0 (n = 1), T3b N1M0 (n = 1) and T4aN1M1 (n = 1). Mean recurrence ± SD (months) occurred at 19.5 ± 2.06 (95% (confidence interval (CI)), 15.5–23.6); mean progression (months) occurred at 23.8 ± 1.46 (95% (CI), 20.9–26.7). Our study suggests that Cyclin D3 gene amplification might be a predictor of aggressiveness in BCG-treated CIS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Lopez-Beltran A (2008) Bladder cancer: clinical and pathological profile. Scand J Urol Nephrol Suppl 218:95–109

    Article  Google Scholar 

  2. Nese N, Gupta R, Bui MH, Amin MB (2009) Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis. J Natl Compr Canc Netw 7:48–57

    PubMed  Google Scholar 

  3. Andius P, Damm O, Holmäng S (2004) Prognostic factors in patients with carcinoma in situ treated with intravesical Bacille Calmette-Guérin. Scand J Urol Nephrol 38:285–290

    Article  PubMed  Google Scholar 

  4. Witjes JA (2004) Bladder carcinoma in situ in 2003: state of the art. Eur Urol 45:142–146

    Article  CAS  PubMed  Google Scholar 

  5. van der Meijden AP, Sylvester R, Oosterlinck W (2005) EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol 48:363–371

    PubMed  Google Scholar 

  6. Sylvester RJ, van der Meijden A, Witjes JA (2005) High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 66(Suppl 1):90–107

    Article  PubMed  Google Scholar 

  7. Shariat SF, Palapattu GS, Karakiewicz PI (2007) Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol 51:152–160

    Article  PubMed  Google Scholar 

  8. Montironi R, Lopez-Beltran A, Scarpelli M, Mazzucchelli R, Cheng L (2009) 2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections. Eur Urol Suppl 8:453–457

    Google Scholar 

  9. Cheng L, Cheville JC, Neumann RM (1999) Survival of Patients with Carcinoma In Situ of the Urinary Bladder. Cancer 85:2469–2474

    Article  CAS  PubMed  Google Scholar 

  10. Gonzalez-Campora R, Davalos-Casanova G, Beato-Moreno A, Lopez-Beltran A (2007) BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma. Cancer Lett 250:292–299

    Article  CAS  PubMed  Google Scholar 

  11. Gofrit ON, Pode D, Pizov G (2009) The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Gúerin immunotherapy. Urol Oncol 27:258–262

    PubMed  Google Scholar 

  12. Wolf H, Melsen F, Pedersen SE, Nielsen KT (1994) Natural history of carcinoma in situ of the urinary bladder Scand. J Urol Néphrol Suppl 157:147–151

    Google Scholar 

  13. Palou J, Laguna P, Millan-Rodriguez F, Hall RR, Salvador-Bayarri J, Vicente-Rodriguez J (2001) Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol 165:1488–1491

    Article  CAS  PubMed  Google Scholar 

  14. Ribal MJ, Alcaraz A, Mengual L (2004) Chromosomal High-Polysomies Predict Tumour Progression in T1 Transitional Cell Carcinoma of the Bladder. Eur Urol 45:593–599

    Article  CAS  PubMed  Google Scholar 

  15. Shariat SF, Kim J, Raptidis G, Ayala GE, Lerner SP (2003) Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 61:1140–1145

    Article  PubMed  Google Scholar 

  16. Hopman AH, Kamps MA, Speel EJ, Schapers RF, Sauter G, Ramaekers FC (2002) Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma. Am J Pathol 161:1119–1125

    CAS  PubMed  Google Scholar 

  17. Shariat SF, Pahlavan S, Baseman AG (2001) E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology 57:60–65

    Article  CAS  PubMed  Google Scholar 

  18. Zlotta AR, Noel JC, Fayt I (1999) Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. J Urol 161:792–798

    Article  CAS  PubMed  Google Scholar 

  19. Hartmann A, Schlake G, Zaak D (2002) Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 62:809–818

    CAS  PubMed  Google Scholar 

  20. Dyrskjøt L, Kruhøffer M, Thykjaer T (2004) Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64:4040–4048

    Article  PubMed  Google Scholar 

  21. Zieger K, Marcussen N, Borre M, Orntoft TF, Dyrskjøt L (2009) Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development. Int J Cancer 125:2095–2103

    Article  CAS  PubMed  Google Scholar 

  22. Lopez-Beltran A, Cheng L, Mazzucchelli R, Blanca A, Montironi R (2008) Morphological and Molecular Profiles and Pathways in Bladder Neoplasms. Anticancer Res 28:2893–2900

    PubMed  Google Scholar 

  23. Schrier BP, Vriesema JL, Witjes JA, Kiemeney LA, Schalken JA (2006) The predictive value of p53, p27(kip1), and alpha-catenin for progression in superficial bladder carcinoma. Eur Urol 50:76–82

    Article  CAS  PubMed  Google Scholar 

  24. Lopez-Beltran A, Requena MJ, Luque RJ, Alvarez J, Montironi R (2006) Cyclin D3 expression in primary Ta/T1 bladder cancer. J Pathol 209:106–113

    Article  CAS  PubMed  Google Scholar 

  25. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, Montironi R (2004) Prognostic Factors in StageT1Grade 3 Bladder Cancer Survival: The Role of G1 + S Modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and Proliferation Index (ki67-MIB1). Eur Urol 45:606–612

    Article  CAS  PubMed  Google Scholar 

  26. Bartkova J, Zemanova M, Bartek J (1996) Abundance and subcellular localization of cyclin D3 in human tumors. Int J Cancer 65:323–327

    Article  CAS  PubMed  Google Scholar 

  27. Birkhahn M, Mitra AP, Williams AJ (2010) Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol 57:12–20

    Article  CAS  PubMed  Google Scholar 

  28. Pruneri G, Pignataro L, Valentini S (2005) Cyclin D3 immunoreactivity is an independent predictor of survival in laryngeal squamous cell carcinoma. Clin Cancer Res 11:242–248

    CAS  PubMed  Google Scholar 

Download references

Acknowledgment

Supported by the grants SAF2007-64942 (Ministry of Education and Research, Madrid, Spain), P07-CVI-02974 and PI0003/2007 (Junta de Andalucia, Seville, Spain). Work at CIC is also funded by Instituto de Salud Carlos III (PI081828, RD06/020/0059). JLO is supported by ISCIII (Contratos Postdoctorales Sara Borrell CD6/00001).

Conflict of Interest Statement

No potential conflicts of interest

Author information

Authors and Affiliations

  1. Department of Pathology, Cordoba University Medical School, Cordoba, Spain

    Antonio Lopez-Beltran

  2. Laboratory of Molecular Pathology, Centro de Investigación del Cáncer-IBMCC, University of Salamanca-CSIC, Salamanca, Spain

    Jose L. Ordóñez, Ana P. Otero, Vicky Sevillano & Enrique de Alava

  3. Biomedical Research Unit, University Hospital, Cordoba, Spain

    Ana Blanca

  4. National Cancer Institute CNIO, Madrid, Spain

    Marta Sanchez-Carbayo

  5. Biostatistics Unit, University Hospital, Cordoba, Spain

    Elisa Muñoz

  6. Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, USA

    Liang Cheng

  7. Institute of Pathological Anatomy and Histopathology, Polytechnic University of the Marche Region, Ancona, Italy

    Rodolfo Montironi

  8. Faculty of Medicine, Unit of Anatomical Pathology, 14004, Cordoba, Spain

    Antonio Lopez-Beltran

Authors
  1. Antonio Lopez-Beltran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jose L. Ordóñez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ana P. Otero
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ana Blanca
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vicky Sevillano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marta Sanchez-Carbayo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Elisa Muñoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Liang Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rodolfo Montironi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Enrique de Alava
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonio Lopez-Beltran.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lopez-Beltran, A., Ordóñez, J.L., Otero, A.P. et al. Cyclin D3 gene amplification in bladder carcinoma in situ. Virchows Arch 457, 555–561 (2010). https://doi.org/10.1007/s00428-010-0969-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-010-0969-6

Keywords

Search

Navigation